Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Roche’s NSCLC Drug Shows Brain Benefits in Two Phase III Trials

By Joanne Van Zuidam | September 6, 2017

Patients with non-small cell lung cancer (NSCLC) have a high risk of central nervous system and brain metastases.

In a head-to-head study with Pfizer’s crizotinib (Xalkori), Roche’s cancer drug alectinib (Alecensa) has shown a far lower risk of cancer spreading to the brain in patients with advanced ALK-positive NSCLC.

New results from the ALEX trial, along with data from the Phase III ALUR trial, will be presented at the European Society for Medical Oncology (ESMO) congress in Madrid. 

In a new subgroup analysis of the Phase III study ALEX, alectinib reduced the risk of disease progression in the central nervous system by 60 percent compared with crizotinib in patients who had existing metastases in the central nervous system. 

In patients without brain disease at the start of testing, alectinib reduced the risk of disease progression in the central nervous system by 49 percent.

In the ALUR study, data showed an 85 percent reduction in risk of disease worsening or death versus chemotherapy in patients who had previously seen their disease worsen on chemotherapy and crizotinib.

ALUR included 107 ALK-positive NSCLC patients whose disease had progressed after a previous first-line combination treatment of both platinum-based chemotherapy and crizotinib.

Patients were randomized to second-line therapy with either standard relapse chemotherapy or alectinib.

Median progression free survival (PFS) was significantly longer in the alectinib group compared to the chemotherapy group—9.6 months versus 1.4 months.

Among patients who had measurable CNS disease at baseline, the central nervous system overall response rate was 54.2 percent in those treated with alectinib compared to zero in the chemotherapy group.

The safety profile of alectinib compared favorably with chemotherapy, despite the substantially longer 20-week duration of treatment for patients on alectinib compared to six weeks with chemotherapy.

“This is another important goal reached in the field of thoracic oncology,” said study investigator Dr. Silvia Novello, University of Turin, Italy. “ALK- positive patients represent 4 percent of patients with advanced NSCLC, which is the leading cause of solid cancer deaths in men and women in several countries. Central nervous system data are extremely relevant for these patients – the brain is a frequent site of metastasis for them – and these results are important because if we’re aiming to prolong survival we must aim to preserve their neurocognitive capacity. A drug which has this activity on brain metastases can allow us to modify treatment and reduce the need for whole brain radiotherapy.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE